NON-TRANSFUSION DEPENDENT BETA-THALASSEMIA (NTDT)

Clinical trials for NON-TRANSFUSION DEPENDENT BETA-THALASSEMIA (NTDT) explained in plain language.

Never miss a new study

Get alerted when new NON-TRANSFUSION DEPENDENT BETA-THALASSEMIA (NTDT) trials appear

Sign up with your email to follow new studies for NON-TRANSFUSION DEPENDENT BETA-THALASSEMIA (NTDT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New shot aims to tame toxic iron in blood disorder

Disease control Recruiting now

This study is testing an experimental drug called REGN7999, given as an injection under the skin, for people with a genetic blood disorder called non-transfusion dependent beta-thalassemia. The main goal is to see if the drug can safely reduce dangerously high levels of iron that…

Matched conditions: NON-TRANSFUSION DEPENDENT BETA-THALASSEMIA (NTDT)

Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control

Last updated Mar 31, 2026 12:12 UTC

NON-TRANSFUSION DEPENDENT BETA-THALASSEMIA (NTDT)

Get alerted when new NON-TRANSFUSION DEPENDENT BETA-THALASSEMIA (NTDT) trials appear

New shot aims to tame toxic iron in blood disorder